November 13th, 2026Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect AnalysisA post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.Read more
November 12th, 2026Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU ControlPost hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.Read more
November 20th, 2026Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MDChildren receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.Read more
November 19th, 2026ABCs in Dermatology: Evolving Therapies and Dermatology's Role in Cutaneous Lupus CareAckerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.Read more
November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more
November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more
November 14th, 2026Early Dupilumab in Pediatric EoE Tied to Lower Incident AsthmaChildren with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.Read more
November 14th, 2026Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal SyndromeNo patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.Read more